title: [Icatibant is a new treatment option in life-threatening angioedema triggered by angiotensin-converting enzyme inhibitor].
abstract: A 78 year-old woman with life-threatening angiotensin-converting enzyme inhibitor (ACE-i) induced angioedema was unresponsive to conventional treatment with corticosteroids, antihistamines and epinephrine. She was successfully treated with icatibant licensed for treatment of hereditary angioedema knowing that both conditions involve bradykinin induced activation of bradykinin B2 receptors. Randomised, controlled trials are warranted to document the efficacy of icatibant in ACE-i angioedema.
authors: Øre-næse-hals Afdeling F, Odense Universitetshospital, 5000 Odense C, Denmark. Soeren.Fast@ouh.regionsyddanmark.dk
authors: Søren
authors: S
authors: Fast
authors: Emil
authors: E
authors: Henningsen
authors: Anette
authors: A
authors: Bygum
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000799:Angioedema / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004656:Enalapril / Q000009:adverse effects*; D005260:Female; D006801:Humans
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004656:Enalapril; C065679:icatibant; D001920:Bradykinin